Acumen Pharmaceuticals
ABOS
71 hedge funds and large institutions have $43.6M invested in Acumen Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 15 increasing their positions, 22 reducing their positions, and 27 closing their positions.
2,200% more call options, than puts
Call options by funds: $46K | Put options by funds: $2K
3% less capital invested
Capital invested by funds: $44.8M → $43.6M (-$1.2M)
4.93% less ownership
Funds ownership: 67.03% → 62.1% (-4.9%)
12% less funds holding
Funds holding: 81 → 71 (-10)
32% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 22
37% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$876K |
| 2 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$828K |
| 3 |
YIH
Y-Intercept (HK)
Hong Kong
|
+$270K |
| 4 |
Jane Street
New York
|
+$177K |
| 5 |
Goldman Sachs
New York
|
+$149K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.19M |
| 2 |
JP Morgan Chase
New York
|
-$877K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$500K |
| 4 |
State Street
Boston,
Massachusetts
|
-$446K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$266K |
ABOS Hedge Fund Activity: Q2 2025 in Review
71 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Acumen Pharmaceuticals (ABOS) for Q2 2025, worth a combined $43.6M — down 2.7% from $44.8M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of ABOS and 17 opened new positions — a net loss of 10 holders — while 22 trimmed existing stakes and 15 added.
The largest buyer was Millennium Management, adding an estimated $876K. The largest seller was BlackRock, cutting an estimated $2.19M.
- 71 institutional investors held Acumen Pharmaceuticals (ABOS) as of Q2 2025, down from 81 in Q1 2025.
- Funds reported $43.6M of Acumen Pharmaceuticals stock for Q2 2025, down 2.7% quarter-over-quarter.
- 17 funds opened new Acumen Pharmaceuticals positions in Q2 2025 and 27 closed out, a net change of -10 holders.
- The largest Acumen Pharmaceuticals buyer in Q2 2025 was Millennium Management, an estimated $876K added.
- The largest Acumen Pharmaceuticals seller in Q2 2025 was BlackRock, an estimated $2.19M sold.
Based on aggregated 13F filings for Q2 2025.